Anti-CD7 CAR
Showing 1 - 25 of >10,000
CD7+ Acute Leukemia, CD7+ Lymphoma Trial in Hangzhou (anti-CD7 CAR-T)
Recruiting
- CD7+ Acute Leukemia
- CD7+ Lymphoma
- anti-CD7 CAR-T
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital,College of Medicine, Zhejiang Univ
Sep 18, 2022
T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma Trial in Shanghai (anti-CD7
Recruiting
- T Lymphoblastic Leukemia/Lymphoma
- +4 more
- anti-CD7 CAR-T cells
-
Shanghai, ChinaXianmin General Song
Aug 29, 2022
T-cell Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma Trial in Kunming (Target CD7 CAR-T cells)
Withdrawn
- T-cell Acute Lymphoblastic Leukemia
- T-lymphoblastic Lymphoma
- Target CD7 CAR-T cells
-
Kunming, Yunnan, China920th Hospital of Joint Logistics Support Force of People's Libe
Nov 23, 2022
T-Cell Acute Lymphocytic Leukemia Trial in Langfang (CD7 CAR-T)
Recruiting
- T-Cell Acute Lymphocytic Leukemia
- CD7 CAR-T
-
Langfang, Hebei, ChinaHebei Yanda Hospital
Jun 26, 2023
Hematological Malignancies Trial (Anti-CD7 CAR-T)
Not yet recruiting
- Hematological Malignancies
- Anti-CD7 CAR-T
- (no location specified)
Jul 8, 2022
T-Cell Lymphocytic Leukemia, T-Cell Chronic Lymphocytic Leukemia, T Cell Non-Hodgkin Lymphoma Trial in Wuhan (Fludarabine +
Recruiting
- T-Cell Lymphocytic Leukemia
- +2 more
- Fludarabine + Cyclophosphamide + CAR7-T Cells
-
Wuhan, Hubei, ChinaUnion Hospital, Huazhong University of Science and Technology
Mar 1, 2022
T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)
Not yet recruiting
- T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- CD7-CART01
- (no location specified)
Sep 26, 2023
T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, T-cell Non-Hodgkin Lymphoma Trial in Shenzhen (CD7 CAR
Recruiting
- T-cell Acute Lymphoblastic Leukemia
- +2 more
- CD7 CAR T cells
-
Shenzhen, Guangdong, ChinaPeking University Shenzhen Hospital
Jun 19, 2021
Diffuse Large B-cell Lymphoma Trial in Hangzhou, Ningbo (CD19-7×19 CAR-T combined with Tislelizumab)
Recruiting
- Diffuse Large B-cell Lymphoma
- CD19-7×19 CAR-T combined with Tislelizumab
-
Hangzhou, Zhejiang, China
- +1 more
Dec 12, 2022
T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)
Not yet recruiting
- T-Cell Non-Hodgkin Lymphoma
- +14 more
- WU-CART-007
-
Saint Louis, MissouriWashington University School of Medicine
Jan 17, 2023
Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia Trial in Philadelphia (BEAM-201)
Recruiting
- Lymphoblastic Lymphoma
- +2 more
- BEAM-201
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Jun 2, 2023
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia
Recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- CAR-20/19-T cells (1 x 10^5 CAR-20/19-T cells/kg)
- +4 more
-
Milwaukee, WisconsinMedical College of Wisconsin
Sep 22, 2022
Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Chronic Lymphocytic Leukemia Trial in Milwaukee (CAR-20/19-T cells (1.0 x10^5
Completed
- Lymphoma, Non-Hodgkin
- +3 more
- CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)
- +3 more
-
Milwaukee, WisconsinFroedtert Hospital & Medical College of Wisconsin
Jun 26, 2022
T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma Trial in Australia, United States (WU-CART-007)
Recruiting
- T-cell Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- WU-CART-007
-
Duarte, California
- +7 more
Jun 22, 2022
Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL Trial in Calgary, Edmonton (autologous CD19-directed
Recruiting
- Relapsed Non Hodgkin Lymphoma
- +2 more
- autologous CD19-directed chimeric antigen receptor (CAR) T-cells
-
Calgary, Alberta, Canada
- +5 more
Jul 18, 2022
DLBCL, Not Otherwise Specified, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial in Seattle
Terminated
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- +5 more
- Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 1, 2022
Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute Adult Trial in Singapore (CAR
Recruiting
- Lymphoblastic Leukemia, Acute, Childhood
- +6 more
- CAR T-cell therapy
-
Singapore, SingaporeAllen Yeoh Eng Juh
Sep 7, 2021
Study for Patients Treat With WU-CART-007
Enrolling by invitation
- T-cell Acute Lymphoblastic Leukemia
- T-cell Lymphoblastic Lymphoma
- Genetic: WU-CART-007
-
Saint Louis, MissouriWashington University
Aug 18, 2022
T-cell Leukemia, T-cell Lymphoma Trial in ChongQing (CD7 UCAR-T cells, Fludarabine, Cytoxan)
Recruiting
- T-cell Leukemia
- T-cell Lymphoma
- CD7 UCAR-T cells
- +3 more
-
ChongQing, Chongqing, ChinaDepartment of Hematology, Xinqiao Hospital
Jun 21, 2021
Systemic Lupus Erythematosus (SLE) Trial in Shanghai (anti-CD19 CAR NK cells (KN5501))
Recruiting
- Systemic Lupus Erythematosus (SLE)
- anti-CD19 CAR NK cells (KN5501)
-
Shanghai, ChinaChanghai Hospital
Aug 25, 2023
Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)
Recruiting
- Extranodal NK T Cell Lymphoma
- NK-Cell Leukemia
- Anti-CD56 CAR T
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023
Hematologic Diseases, Tumors Trial in Hangzhou (CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation)
Recruiting
- Hematologic Diseases
- Neoplasms
- CD7 CAR-T cells injection
- Allogeneic hematopoietic stem cell transplantation
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Apr 11, 2023
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto
Not yet recruiting
- Multiple Sclerosis
- +2 more
- KYV-101 anti-CD19 CAR-T cell therapy
- Standard lymphodepletion regimen
-
Palo Alto, CaliforniaStanford Multiple Sclerosis Center
Nov 13, 2023
Leukemia, T Cell Trial in Beijing (CD7 CART)
Recruiting
- Leukemia, T Cell
- CD7 CART
-
Beijing, Hebei, ChinaHe bei Yan da Lu dao pei Hospital
May 24, 2022
Tumors, Hematologic Tumors, Tumors by Site Trial in Hangzhou (RD13-02 cell infusion)
Recruiting
- Neoplasms
- +3 more
- RD13-02 cell infusion
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Feb 6, 2023